Genetics may affect anti-clot med

Variants of a gene called CYP2C19 affect how well a person converts clopidogrel (Plavix) to its active anti-clotting form in the body, according to Harvard Health.

About 30 percent of people poorly metabolize the anti-clotting drug, leaving them at higher risk for blood clots. People with this genetic variant could take alternative anti-clotting drugs, such as Effient or Brilinta.